Close Menu

More articles about Diagnostics

The firm is developing a portable, rapid MDx platform for infectious disease testing in clinics, and anticipates launching a first product in 2020.

Reanalyzing clinical exomes from 2011 to 2013 increased molecular diagnostic yields significantly, leading to clinical management changes, in some cases.

Interpace Diagnostics' ThyGeNext and ThyraMir thyroid cancer assays are now covered for about 2.5 million patients in Philadelphia and Southeastern Pennsylvania.

McKesson will be the exclusive distributor of the QiaStat-Dx system in US hospitals with fewer than 200 beds and non-exclusive distributor for future expansion into retail pharmacy clinics.

The new grant will be used to conduct whole-exome sequencing on 1,000 children participating in an autism spectrum disorder study for the purposes of biomarker development.

The complaint alleges that NeuMoDx is willfully infringing on six BD-held patents, and demands injunctive relief, damages, and a jury trial.

The LeukoStrat CDx FLT3 Mutation Assay can now be used in Japan as the CDx for quizartinib for the treatment of FLT3-ITD positive relapsed or refractory AML.

Resolution is developing its liquid biopsy assay as a companion diagnostic for niraparib in metastatic castration-resistant prostate cancer.

The drug is for first-line maintenance therapy after BRCA-mutated advanced ovarian cancer patients respond to platinum chemo and the test will identify those with BRCA mutations.

The center will use Qiagen Clinical Insight to analyze, interpret, and report molecular screening of cancer patients to help identify targeted therapies and clinical trial options.

Adaptive currently offers a clinical immunosequencing assay for monitoring minimal residual disease in multiple myeloma and acute lymphoblastic leukemia.

The firm, Phenomix Sciences, anticipates that its test will help drive adoption of medications for obesity at a time when patients are reluctant to take them.

The agreement follows a number of other distribution deals Bioké has signed in recent months including ones with Omni Life Science, Syntec, and Namocell.

The high-throughput, scalable BD Cor system for infectious disease diagnostics is now available in Europe with the firm's BD Onclarity HPV assay. 

The funding will support development of a test for the Zika virus using Ontera's silicon nanopore-based molecular diagnostics platform.

A UK court determined that Ariosa's licensee infringed upon at least one claim of Illumina's European patent 1 524 321 and upheld the patent's validity.

CPIC wants to issue guidelines for non-actionable genes, standardize PGx terms, and work with groups like ClinGen and ClinVar to expand use of its guidelines.

The firm is validating two biomarkers that it hopes will stratify patients for its investigational drug for pediatric minimally verbal autism.

The acquisition will bring to Invitae single-molecule, cell-free DNA analysis technology and enable lower cost NIPS testing.

Patients who enroll will have their samples tested as part of routine diagnostic care, making it easier for them to take part in clinical trials without additional testing.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.